Liquet™ Medical Inc. Receives FDA 510(k) Clearance for the Versus™ Catheter: Hemodynamics-Led Thrombolysis (HLT) allows Physicians to Personalize the Treatment of Blood Clots in the Lungs utilizing Real-Time Pulmonary Artery Pressure.
Liquet Medical Inc., a pioneering medical device company committed to advancing patient care through innovative technologies, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Versus™ Catheter. This innovative medical device is set to enhance the treatment of pulmonary artery blood clots by offering real-time pulmonary artery pressure measurements, empowering clinicians to optimize treatment based on individual patient responses. This novel technology enables a new treatment category called “Hemodynamics-Led Thrombolysis (HLT).”
